Clinical trials: Autoimmune Liver Disease
Liver Cirrhosis
Transient Elastography in Autoimmune Hepatitis
Recent, research has focused on the evaluation of non-invasive methods for the assessment of liver fibrosis in patients with chronic liver disease. Among these methods, transient elastography is the most promising.
- Trial name
- NCT01905254
- Testing
- Transient elastography (TE), Liver biopsy
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Autoimmune Hepatitis
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs.
- Trial name
- NCT00608894
- Testing
- LCP-Tacro (tacrolimus), Azathioprine
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Veloxis Pharmaceuticals
Liver Disease
Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to…
- Trial name
- NCT00206076
- Testing
- mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Albert Einstein Healthcare Network
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period…
- Trial name
- NCT05569759
- Testing
- zetomipzomib, zetomipzomib in open-label extension
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kezar Life Sciences, Inc.
Autoimmune Hepatitis, Autoimmune Chronic Hepatitis
Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)
The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.
- Trial name
- NCT04790916
- Testing
- RO7049665
- Where
- 14 sites in Australia, Canada and 6 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
The purpose of this study is to learn if giving multiple doses of a hormone called glucagon can cause a major decrease in liver glycogen (animal starch).
- Trial name
- NCT01986231
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Legacy Health System
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Autoimmune Hepatitis
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS
The purpose of this study is to study the safety and tolerability of synthetic PreImplantation Factor (sPIF) in female patients with autoimmune hepatitis.
- Trial name
- NCT02239562
- Testing
- sPIF
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Christopher O'Brien, MD
Autoimmune Hepatitis
Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial
The gold-standard treatment of Autoimmune hepatitis (AIH), with prednisone alone or in conjunction with azathioprine can reach resolution of the disease in 70-80% of the cases in US.
- Trial name
- NCT02463331
- Testing
- Chloroquine diphosphate, prednisone, azathioprine
- Volunteers
- 57 people
- Sponsor
- University of Sao Paulo General Hospital
Type 1 Diabetes Mellitus
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with…
- Trial name
- NCT02093221
- Testing
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI
- Where
- 36 sites in United States
- Volunteers
- 76 people
- Sponsor
- Grifols Therapeutics LLC